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Background: 5-fluorouracil (5-FU) is employed to enhance radiotherapy (RT) effect. Here, we evaluated the influence
of whole-pelvic irradiation on the pharmacokinetics (PK) of 5-FU in plasma and lymphatic system of rats as the
experimental model.
Methods: RT with 2 Gy was delivered to the whole pelvis of Sprague–Dawley rats. 5-FU at 100 mg/kg was
intravenously infused 24 hours after radiation. The pharmacokinetics of 5-FU in plasma and lymphatic system
were calculated.
Results: RT at 2 Gy reduced the area under the plasma concentration vs. time curve and mean residence
time of 5-FU by 21.5% and 31.5%, respectively compared with those of non-RT controls. By contrast, RT at
2 Gy increased drug clearances of 5-FU by 28.2% when compared with those of non-RT controls. There was
no significant difference in T1/2, Cmax and Vss in plasma between both groups. Intriguingly, 5-Fu could be
detected in the lymphatic system. In addition, the AUC in 5-FU without and with RT was 3.3-fold and 4.9-fold
greater for lymph than for plasma, respectively. Compared with the non-RT group, the RT group showed
increase in distribution of 5-FU in the lymphatic system (p = 0.001).
Conclusions: The local whole pelvic RT at 2 Gy could modulate systemic PK of 5-FU in plasma of rats and
intravenous 5-FU passing into the lymphatic system was proved. The metabolism of 5-FU might be modulated
by RT but the distribution of 5-FU from blood circulation to the lymphatic system might not be changed. The RT-PK
phenomena in plasma provide references for adjustment of drug administration. Chemotherapy drugs entering the
lymphatic system is worthy of further investigation.
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Five-fluorouracil (5-FU) is one of the most commonly
used chemotherapeutic agents of concurrent chemoradi-
ation therapy (CCRT) for enhancing radiation therapy
(RT) effects [1-4]. Lymph node metastases are common
among rectal cancer patients with incidence ranging be-
tween 5% and 35% even in T1 and T2 stages [5]. For T3,
T4 or node-positive rectal cancer patients, adjuvant CCRT
improves the locoregional failure control and overall sur-
vival by 10-15% when compared with surgery or adjuvant* Correspondence: thtsai@ym.edu.tw; chenmdphd@gmail.com
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unless otherwise stated.RT alone [6-8]. Further, neoadjuvant CCRT followed by
surgery also improves locoregional control for rectal can-
cer patients [9]. CCRT reduces the risks of local recur-
rences and regional lymph node metastases.
Growing evidence shows that irradiation may not only
has DNA damage effects but also sends signals to their
neighborhood, the so-called as bystander effect [10,11]
or longer-range effects such as the abscopal effects [12].
Our recent studies reported that local RT could modu-
late the systemic pharmacokinetics (PK) of 5-FU with
different RT doses in an experimental rat model [13,14]
through matrix metalloproteinase-8 (MMP-8) [15].
RT may inevitably damage normal tissue and impair
the vascular and lymphatic system which could occurhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing the vascular permeability [17]. While most of the
aforementioned studies reported that RT modulates the
PKs of 5FU in the plasma, whether RT modulates PKs in
the lymphatic system remains largely unknown. The
present study investigates the pharmacokinetics of 5-FU
in the plasma and lymphatic system in rats with and
without RT. Results thus obtained might provide new in-
sights into the RT-PK phenomena of 5-FU.
Methods
Materials and reagents
5-FU and ethyl acetate were purchased from Sigma-Aldrich
Chemicals (St. Louis, MO, USA). High-performance liquid
chromatography (HPLC)-grade methanol was obtained
from Tedia Co., Inc. (Fairfield, OH, USA). Milli-Q grade
(Millipore, Bedford, MA, USA) water was used for the
preparation of solutions and mobile phases.
Preparation of standard solutions
The standard stock solution was prepared by dissolving
5-FU in Milli-Q water at a concentration of 1 mg/mL
and stored at −20°C. The stock solution was diluted with
Milli-Q water to prepare a series of working standard so-
lutions. The calibration curves were generated by spiking
standard solutions (10 μL) in blank rat plasma or lymph-
atic fluid (90 μL) and then extracted by ethyl acetate.
Instrumentation and High performance liquid
chromatography (HPLC) conditions
Chromatographic separation was performed with a Shimadzu
system, equipped with a chromatographic pump (LC-20AT),
an autosampler (SIL-20 AC), a DGU-20A5 degasser and a
photo-diode array detector (SPD-M20A) (Shimadzu, Kyoto,
Japan). A LiChroCART RP-18e column (Purospher, 250 ×
4 mm; particle size, 5 μm, Merck, Darmstadt, Germany)
with a LiChroCART 4–4 guard column was used for sep-
aration. The mobile phase comprised 10 mM potassium
phosphate-methanol (99:1, v/v, pH 4.6), and the flow rate
was set at 1 mL/min. The injection volume was 20 μL.
The detection wavelength was set at 266 nm. Under these
conditions, the retention time of 5-FU was 5.4 min. The
linearity of calibration curves was demonstrated by the
good determination coefficients (r2) obtained for the re-
gression line.
Method validation
The method validation assays were carried out according to
the currently accepted US Food and Drug Administration
(FDA) bioanalytical method validation guidance for specifi-
city, linearity, sensitivity, precision, accuracy and recovery.
Standard working solutions were obtained by making ap-
propriate dilutions. The concentrations utilized for the
calibration curves were 0.5-100 μg/mL for 5-FU. All linearcurves were required to have a coefficient of estimation of
at least >0.995. The calibration function was constructed
by determining the best-fit of peak area. Both intra- and
inter-day variability were determined by quantitating six
replicates at linear concentrations using the HPLC-UV
method described above on the same day and six consecu-
tive days, respectively. The precision (RSD %) and accur-
acy (bias %) of the analytical method were calculated for
evaluation. The extraction recovery of 5-FU from plasma
and lymphatic fluid were determined by comparing the
peak area of extracted standard in the biological samples
with the peak area of standard spiked in neat mobile
phase. The accuracy within the calibration range was eval-
uated by the nominal concentration (Cnom) and the mean
value of the observed concentrations (Cobs) as follows: ac-
curacy (bias, %) = [(Cobs - Cnom)/Cnom] × 100. The preci-
sion, relative standard deviation (RSD), was calculated from
the observed concentrations as follows: RSD (%) = [stand-
ard deviation (SD)/Cobs] × 100.
Preparation of animals and samples
Both animals and samples were prepared was according
to our previous reports [15]. Briefly, adult male Sprague–
Dawley rats (300 ± 20 g body weight) were provided by
the Laboratory Animal Center at National Yang-Ming
University (Taipei, Taiwan). The surgical and experimental
protocols involving animals were reviewed and approved
by the Institutional Animal Care and Use Committee of
National Yang-Ming University (IACUC number: 1020707).
They were housed in a specific pathogen-free environment
and had free access to food (Laboratory Rodent Diet 5001,
PMI Nutrition International LLC, MO, USA) and water.
For radiotherapy, the rats were anesthetized with pento-
barbital sodium (50 mg/kg, i.p.), and were immobilized on
a board to undergo computed tomography for simulation
of the whole pelvic field. The cranial margin was set at the
top of bilateral iliac crest for the whole pelvic field. Con-
ventional radiotherapy was employed to deliver the radi-
ation dose through anterior-posterior (AP) and PA portals.
The experimental animals were randomized to control
(0 Gy) and 2 Gy groups. Data were obtained from 6 rats in
each group.
The reason why using 2 Gy for rats to simulate the rele-
vant dose for daily treatment of human torso is safe and
workable has been described in our previous report [13].
Briefly, there was no direct comparison of allometric scal-
ing using whole-pelvic irradiation. Nonetheless, the allo-
metric scaling of the lethal dose (LD50) (Gy) of total-body
irradiation for human and rat are 4 Gy and 6.75 Gy, re-
spectively [18]. In view of the moderate difference, 2 Gy is
used for rats to simulate the relevant dose for daily treat-
ment of human torso.
Ambre et al. [19] studied the elimination of 5-FU and its
metabolites to rats. The results of that study suggested
Figure 1 Anatomy of mesenteric lymphatic duct. Light blue arrow
indicates the mesenteric lymphatic duct.
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intravenous administration of 5-FU at 150 mg/kg. When
rats were administered 5-FU at 10, 50, or 100 mg/kg in
2 mL of normal saline by intravenous infusion over a 2-min
period via the cannula [20] and the dose-normalized area
under the curve (AUC) was significantly higher after ad-
ministration of 100 mg/kg than of 50 mg/kg or 10 mg/kg.
The clinical pharmacokinetics of single doses of 5-FU
from 300 to 600 mg/m2, administered as intravenous bolus,
had been characterized previously [21]. The formula which
is used to dose translation from animal to human: human
equivalent dose (HED, mg/kg) =Animal dose (mg/kg) multi-
ply by animal Km/human Km [22]. Furthermore, the rec-
ommended volume for intravenous (bolus) administration
was 5 mL/kg for rats over a short period of approximately
1 min and the rate should not exceed 3 mL/min for ro-
dents [23]. Based on these studies, we chose 100 mg/kg in
2 mL of normal saline by intravenous infusion over a 2-
min period as a feasible 5-FU dose in rats for examination
of 5-FU pharmacokinetic parameters.
For the collection of lymphatic fluid and blood, the rat
was given 2 mL of olive oil by oral gavage 30 min before
operation to facilitate identification of the lymph duct
[24], and then anaesthetized with urethane (1 g/kg) intra-
peritoneally. Surgical sites were shaved and disinfected
with 70% ethanol solution, and polyethylene tubes (PE50)
were then implanted into the right jugular vein and left
carotid artery for intravenous infusion (normal saline,
2 mL/h) and blood sampling, respectively. The procedure
of mesenteric lymph vessel cannulation was performed as
previously reported with modification [25]. Briefly, a mid-
line laparotomy was performed from the xyphoid, intes-
tinal mass was displaced with gauze, and the wound was
retracted by a 3–0 suture. Mesenteric lymph vessels were
easily identified, since they contain white lymph. The mes-
enteric lymph duct was isolated by teasing away the sur-
rounding tissue with a cotton swab. A small cut was made
by a needle, and a silicone tubing (10 cm in length) was
inserted into the mesenteric lymph duct (Figure 1). A drop
of tissue cement was applied to the hole in the lymph duct
to seal it and to fix the cannula in place. The rats were ad-
ministered 100 mg/kg 5-FU in 2 mL of normal saline by
intravenous infusion into the right jugular vein over a 2-
min period [20]. Then, 200-μL blood samples were with-
drawn from the cannula implanted in the carotid artery
into a heparin-rinsed vial at 0, 5, 15, 30, 45, 60, 90, 120,
150, 180, 210 and 240 min. The lymph was collected in
heparinized eppendorf tubes at 30-min intervals. The rat
was intravenously infused with normal saline at infusion
rate of 2 mL per hour throughout the experiment. The
samples were immediately centrifuged at 6000 rpm for
10 min.
The resulting plasma and lymphatic fluid (100 μL, re-
spectively) were extracted by ethyl acetate for liquid-liquid extraction. The biological samples were extracted
by 1 mL of ethyl acetate twice, vortexed for 5 min, and
centrifuged at 13,000 rpm for 10 min. After centrifuga-
tion, the upper organic layer containing the ethyl acetate
was transferred to a new tube and evaporated to dryness
using a vacuum pump. The dried residue was reconsti-
tuted with 100 μL of mobile phase. A 20-μL aliquot of
the solution was injected to the high-performance liquid
chromatography-ultraviolet (HPLC-UV) detection system.
The plasma and lymphatic fluid samples were diluted by
blank plasma and lymphatic fluid samples at an appropri-
ate ratio before analysis if the 5-FU concentration was
exceeded 100 μg/mL.
Pharmacokinetics
Pharmacokinetic calculations were carried out using a
non-compartmental model with the software WinNonlin
Standard Edition Version 1.1 (Scientific Consulting Inc.,
Apex, NC).The areas under a plot of drug concentration
versus time curves (AUC) were calculated according to
the log linear trapezoidal method. The clearance of the
drug (CL) was calculated as follows: CL = dose/AUC. The
time required to reduce the drug concentration by half
is shown as half-life (T1/2) and were expressed as T1/2 =
0.693/K, where K is the first-order rate constant. The vol-
ume of distribution (Vd) was evaluated as Vd = dose/C0,
where C0 is the drug’s plasma concentration. The mean
residence time (MRT) was estimated as MRT =AUMC/
AUC, where AUMC is the area under the first moment
curve. All data are presented as mean ± SEM.
Statistical methods
The results are presented as mean ± standard error mean
(SEM). Differences in actuarial outcomes between the
groups were calculated using Student’s t test. A p value
of < 0.05 was considered significant. All analyses were
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Chromatographic conditions, especially analytical columns
and mobile phase compositions (concentration of buffer,
pH value of the buffer and percentage of the organic mod-
ifiers), were optimized to achieve good sensitivity and peak
shape, as well as a relatively short run. It was observed
that methanol gave a better peak shape than acetonitrile,
and was therefore selected as the organic phase. Finally, a
mobile phase consisting of methanol- 10 mM KH2PO4 so-
lution (pH 4.5) was used in the experiment. There was no
interference under the present analytical conditions during
the retention time of 5-FU which was eluted at 5.1 min.
The peak of 5-FU was well separated and there was no en-
dogenous interference in the rat plasma and lymphatic
fluid samples. Further, the selectivity was tested by chro-
matograms of blank plasma and lymphatic fluid spiked
with 5-FU standard. Good linearity was achieved in the
range of 0.5–50 μg/mL, with all coefficients of correlation
greater than 0.995.
The extraction recoveries of 5-FU at low (1 μg/mL),
medium (10 μg/mL) and high (100 μg/mL) concentrations
in rat plasma versus lymphatic fluid were 59.53 ± 1.83%
versus 57.58 ± 1.71%, 56.24 ± 2.24% versus 53.23 ± 5.17%,
56.19 ± 6.65% versus 57.08 ± 2.19%, and with an average of
57.32 ± 4.25% versus 55.96 ± 3.76%, respectively (Table 1).
Intra-day and inter-day precision (% RSD) and accuracy
(% Bias) were determined by repeated analysis of six lots of
biological samples spiked with different concentrations of
5-FU on the same day and six consecutive days, respect-
ively. Precision and accuracy are presented in Table 2. The
range of intra-day precision and accuracy in rat plasma
versus lymphatic fluid were 0.08% to 18.90% and −5.55%
to 2.25% versus 0.02% to 8.67% and −2.74% to 7.60%, re-
spectively. In rat plasma versus lymphatic fluid, the inter-
day precision and accuracy ranged from 1.30% to 16.58%Table 1 Recovery of 5-FU in rat plasma and lymphatic fluid









Data expressed as mean ± SD (n = 6). Recovery calculated as the ratio of the mean p
of an analyte spiked in the neat mobile phase (set 1) multiplied by 100.and −4.80% to 1.57% versus 0.46% to 5.72% and −0.45%
to 3.06%, respectively. The limit of detection (LOD) and
quantification (LOQ) of 5-FU in rat plasma and lymphatic
fluid were 0.25 and 0.5 μg/mL, respectively.
Pharmacokinetics of 5-FU in rats
The concentration versus time curves of 5-FU in rat
lymphatic fluid and plasma with or without radiation ther-
apy (RT) after 5-FU administration (100 mg/kg, i.v.) to six
individual rats for each group are illustrated in Figure 2
and the pharmacokinetic parameters are presented in
Table 3. The parameters of PKs of 5-FU in lymphatic fluid
with or without irradiation showed no significantly statistical
differences. Intriguingly, the AUC of 5-FU in the lymphatic
system could be detected suggesting that 5-FU can pass
through into the lymphatic system. In addition, the AUC
in 5-FU without RT group was 3.3-fold greater for lymph
than for plasma. The AUC in 5-FU with RT group was
4.9-fold greater for lymph than for plasma (p = 0.001).
The present results reconfirmed the RT-PK phenomena
in the plasma as previously reported that irradiation at
2 Gy markedly reduced the AUC and MRT of 5-FU in rats
plasma by 28.6% and 23.8%, respectively. By contrast, ir-
radiation increased the CL of 5-FU by 39.4% when com-
pared with nonirradiated controls. There was no significant
difference in T1/2, Cmax and Vss between both groups.
Discussion
HPLC-UV detection method was employed to separate
5-FU from plasma and lymphatic fluid samples. After
optimizing the detection conditions, experiments were
conducted to optimize the chromatographic separation
of the analyses. Good linearity was achieved in the range
of 0.5–50 μg/mL, with all coefficients of correlation
greater than 0.995. There was no interference under the
present analytical conditions of 5-FU in rat plasma and
lymphatic fluid (Table 1). The accuracy and precision of
the concentrations were all acceptable (Table 2). The re-
sults suggested that the analytical method was repeatable
and reliable.et 1 Peak area Set 2 Peak area Recovery (%)
6301 ± 412 39467 ± 1211 59.53 ± 1.83
32542 ± 4183 355741 ± 14191 56.24 ± 2.24
463129 ± 22755 3631833 ± 429923 56.19 ± 6.65
57.32 ± 4.25
6301 ± 412 38174 ± 1136 57.58 ± 1.71
32542 ± 4183 336695 ± 32677 53.23 ± 5.17
463129 ± 22755 3689380 ± 141268 57.08 ± 2.19
55.96 ± 3.76
eak area of an analyte spiked before extraction (set 2) to the mean peak area
Table 2 Intra- and Inter-day precision (% RSD) and accuracy (% Bias) of the HPLC-UV method for determination of 5-FU
















Plasma 0.5 0.47 ± 0.09 18.90 −5.55 0.48 ± 0.08 16.58 −4.30
1 1.02 ± 0.08 7.91 2.25 1.02 ± 0.09 8.81 1.57
5 4.87 ± 0.24 4.91 −2.58 4.79 ± 0.38 8.00 −4.80
10 10.15 ± 0.28 2.75 1.52 10.10 ± 0.22 2.13 0.99
50 49.98 ± 0.04 0.08 −0.04 50.29 ± 0.66 1.30 0.58
Lymphatic 0.5 0.54 ± 0.03 8.67 7.60 0.51 ± 0.03 5.72 1.98
fluid 1 1.06 ± 0.06 5.24 6.30 1.03 ± 0.05 4.63 3.06
5 4.86 ± 0.19 3.96 −2.74 4.98 ± 0.11 2.24 −0.45
10 10.03 ± 0.13 1.31 0.30 10.03 ± 0.13 1.27 0.28
50 50.01 ± 0.01 0.02 0.01 49.91 ± 0.23 0.46 −0.17
Data expressed as mean ± SD.
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tabolite kinetics in the body and what the body does to
the drugs [26], including chemical taken appropriately
into the body (absorption), distributed to the right parts
of the body, metabolized in a way that does not instantly
remove its activity, and eliminated in a suitable manner
[27]. In the current study, the mean extraction recover-
ies of 5-FU in rat lymphatic fluid and plasma were 56 %
and 57%, respectively (Table 1). The original form of 5-
FU could be detected in the mesenteric lymphatics as in
the plasma with or without RT suggesting that intraven-
ous injection of 5FU can pass from the blood into the
lymphatic system.
Here, RT at 2 Gy decreased markedly the AUC of 5-FU
by 29% in rats plasma, thus reconfirming the RT-PK phe-
nomena of 5-FU as previously reported [13-15]. The PriorFigure 2 The concentration versus time curves of 5-FU in rat plasma
and lymphatic fluid with or without irradiation therapy (RT) after 5-FU
administration (100 mg/kg, i.v.). Data are expressed as mean± SEM (n = 6).research showed that protein binding of 5-FU in rat
plasma was not affected by RT [13]. Additionally, the
AUC and MRT of 5-FU in the bile increased while the
clearance reduced significantly after RT, suggesting that
local RT could facilitate the excretion of 5-FU [15]. Inter-
estingly, the AUC in 5-FU was 4.9-fold greater for lymph
than for plasma in the RT group but was 3.3-fold in the
non-RT group (p = 0.001), however, the concentration of
5-FU in lymphatic fluid and AUC in RT group was not dif-
ferent from that in the control group (Figure 2). Consider-
ing the parameters of PK in the plasma of 5-FU, there was
not significant different in Vss but with higher CL in RT
group (Table 3). These results suggest that the metabolism
of 5-FU might be changed by RTand the distribution from
blood circulation to the tissues might not be changed.
Radiotherapy may inevitably damage normal tissue and
impair the vascular and lymphatic systems, thus causing
endothelial cell loss [17] and hypertrophy of surviving
endothelial cells [28], which has been associated with en-
hanced vascular permeability. Radiation-induced increase
in vascular permeability is dose dependent between 5- and
20-Gy single doses [29]. It is known that ionizing radiation
commonly increases capillary permeability to fluids even
within one hour after irradiation [16]. However, much less
is understood about the influence of daily RT dose for an-
tineoplastic agents in the lymphatic system. Modification
of chemotherapeutic formulation to increase the lymph-
atic exposure could be a strategy to modulate drug efficacy
[30]. For example, increase in docetaxel concentration in
circulation and decrease in such concentration t in mesen-
teric lymph node were accompanied with enhanced anti-
tumor efficacy [31]. However, the biological meaning of
drug concentration detected in visible gross lymph nodes
may differ from that detected in identifiable lymphatic
vessels. Little is known about the volume of lymphatic
Table 3 Estimated pharmacokinetic parameters of 5-FU in rats after 5-FU administration (100 mg/kg, i.v.)
Parameters Plasma Lymphatic fluid
Without RT With RT Without RT With RT
AUC (min μg/mL) 4353 ± 257 3108 ± 114* 14240 ± 734 15251 ± 1195
T1/2 (min) 28 ± 0.93 26.6 ± 1.67 30.0 ± 6.49 24.4 ± 1.98
Cmax (μg/mL) 119 ± 11.3 102 ± 8.4 153 ± 6.2 163 ± 9.45
CL (mL/min/kg) 23.1 ± 1.41 32.2 ± 1.25* 7.1 ± 0.37 6.73 ± 0.46
MRT (min) 34 ± 1.37 25.9 ± 1.97* 26.3 ± 1.97 27.6 ± 2.38
Vss (mL/kg) 834 ± 63.4 863 ± 50.3 192 ± 20.7 191 ± 26.1
Data expressed as mean ± SEM (n = 6). AUC, area under the concentration versus time curve; T1/2, elimination half-life; Cmax, the peak plasma concentration of a drug
after administration; CL, total body clearance; MRT, mean residence time; Vss, volume of distribution. *significantly different from without RT group at p < 0.05.
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lymphatic system after administration [32]. This uncer-
tainty combined with our previous finding of abscopal ef-
fect of RT on 5-FU PK may have some impact on clinical
practice of CCRT in a statue out of current knowledge
level and merits further scientific investigation. In the
current study, the parameters of PK of 5-FU in lymphatic
fluid were no differences between with or without RT
groups (Table 3). It hints that single daily RT dose would
not change the permeability of vessel or lymphatic system
in delivery of 5-FU.
Compared with surgery alone, neoadjuvant or adjuvant
RT for locally advanced rectal cancer could reduce the
risk of local recurrent [33]. However, adjuvant CCRT for
T3 or T4 or node-positive rectal cancer patients had bet-
ter recurrent-free survival, overall survival and lower local
recurrent rates than adjuvant RT alone [8]. Similarly, neo-
adjuvant CCRT also achieves lower rates of recurrence
than RT alone [34]. The lymphatic system is a chief com-
ponent of the immune system and acts as a secondary cir-
culation system to drain excess fluids, proteins and waste
products from the extracellular space into the vascular
system [35]. The regional lymph nodes, once invaded by
tumor cells, act as reservoirs where cancer cells take root
and seed into other parts of the body [36-39]. The metab-
olism of 5-FU might be modulated by RT and the distribu-
tion from blood circulation to the tissues might not be
changed. Additionally, 5-FU can pass through into the
lymphatic system. The current analysis sheds light on am-
biguities of prior data and may be useful for explaining
why CCRT had better locoregional control rates than RT
alone in either neoadjuvant or adjuvant setting for locally
advanced rectal cancer patients.
The liver catabolyzes about 80% of 5-FU via the dihy-
dropyrimidine dehydrogenase (DPD) pathway, a rate lim-
iting step in the catabolism of 5-FU [40], to generate toxic
5-fluoro-5,6-dihydro-uracil (5-FDHU) [41]. The anabolic
pathway, via orotate phosphoribosyl transferase (OPRT),
produces active metabolites including 5-fluorouridine- 5’-
monophosphate (FUMP), 5-fluorouridine (5-FUrd), and
5-fluoro-2'-deoxyuridine (5-FdUrd) [42]. The severity ofadverse events was associated with increased 5-FU/5-
FDHU AUC ratio [43]. In the current study, the AUC of
5-FU in the plasma after RT was decreased. Further, the
metabolism of 5-FU might be modulated by RT but not
the distribution from blood circulation to the tissues. It is
worth to investigate the effects of RT on the metabolism
of 5-FU in the future to provide useful information for
therapeutic drug monitoring of 5-FU to reduce the risk of
developing severe toxicities after drug administration con-
current with radiotherapy.
Conclusion
To our best knowledge, this is the first study proving that
local irradiation can significantly modulate the systemic
pharmacokinetics of 5-FU. The metabolism of 5-FU might
be modulated by RT and the distribution from blood circu-
lation to the tissues might not be changed. This study may
provide an experimental clue to understanding the unex-
plained biological enhancement of antineoplastic agents in
the era of pelvic CCRT for improving locoregional control
of locally advanced rectal cancer patients.
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